Cefepime–Zidebactam for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria, Including Metallo-β-Lactamase Producers: A Phase 2, Open-Label, Single-Arm, Multicenter Study

Clicks: 3
ID: 333717
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #601 of 626 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 626 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Infections caused by carbapenem-resistant (CR) Gram-negative bacteria, particularly metallo-β-lactamase (MBL)-producers, have limited treatment options. Cefepime–zidebactam retains activity against these pathogens, but clinical data are limited. Methods This prospective, open-label, single-arm, multicenter phase 2 trial enrolled adults with CR Gram-negative infections. Participants received intravenous cefepime–zidebactam for 7–21 days with renal dose adjustment. The Micro-ITT population included participants with a confirmed qualifying CR Gram-negative pathogen, and the CME population included those meeting prespecified evaluability criteria. The primary endpoint was investigator-assessed clinical cure at TOC in the CME population. Outcomes were also reviewed by an external adjudication committee. Results Seventy-two participants received treatment; 68 were included in the Micro-ITT population and 60 in the CME population. Among 68 qualifying isolates, 56 (82.4%) were MBL producers, predominantly NDM-β-lactamase producers. Investigator-assessed clinical cure at test-of-cure in the CME population was 91.7% (95% confidence interval, 81.6%–97.2%), and favorable microbiological outcome at TOC was 90.0%. Among participants in the CME population with MBL-producing pathogens, clinical cure was 93.9% and favorable microbiological outcome was 91.8%. External adjudication in the CME population yielded clinical cure of 86.7% and favorable microbiological outcome of 85.0%. Twenty-eight-day mortality was 2.8%. Treatment-related adverse events occurred in 15.3%, and serious treatment-related adverse events occurred in 2.8%. Conclusions In 60 evaluable adults with carbapenem-resistant Gram-negative infections, predominantly MBL-producing (81.7%) and cUTI/AP (58.3%), investigator-assessed TOC clinical cure was 91.7%; post hoc adjudicated cure was 86.7%. Day 28 all-cause mortality was 2.8%, and cefepime zidebactam was well tolerated.
Reference Key
openalex_W7223277161 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rajiv Karthik K, Dilip Dubey, Rahul Vasantrao Sonawane, Prashant Raghunath Potdar, Deepak Kumar, Pratikshit Madhav Mahajan, Deepesh Gokulchand Aggarwal, Vishnu Rao Polati, Venkatasubramanian Ramasubramanian, Dorairajan Suresh Kumar, Umang Agrawal, Tirlangi Praveen Kumar, Nitin Ranjan Gupta, Vasant Chandrakant Nagvekar, S. Subramanian, Mukesh Kalla, Abi Manesh S, Balaji Veeraraghavan, Thomas L Holland, Adrian John Brink, Souha Sami Kanj, Nicholas Turner, Carlos Roberto Veiga Kiffer, Robert A. Bonomo, Parikshit Shirish Prayag, Thomas P. Lodise
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag665
URL
https://doi.org/10.1093/cid/ciag665
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.